GYRE

Business Context and Reporting Period

This Form 8-K reports on the 2010 Annual Meeting of Stockholders for Targacept, Inc. held on June 10, 2010. The filing details the results of matters submitted to a vote by security holders. Note: The input metadata references "Gyre Therapeutics, Inc.," but the filing text explicitly identifies the registrant as "Targacept, Inc."

Key Financial Metrics

This filing is a Current Report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes and Voting Results

As of the record date (April 14, 2010), there were 28,344,707 shares of common stock issued and outstanding eligible to be voted. All matters submitted were approved by the requisite vote.

1. Election of Directors (Class I)

The following directors were elected to serve until the 2013 annual meeting:

There were 4,950,309 broker non-votes regarding the election of directors.

2. Ratification of Auditors

Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2010.

Guidance, Outlook, and Risks

The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It refers to the Company's proxy statement for a more complete description of the matters voted upon.

Investor Verification Checklist

• Verify the registrant name is Targacept, Inc., not Gyre Therapeutics, Inc.
• Confirm the total number of shares eligible to vote (28,344,707) against the sum of votes cast, withheld, and broker non-votes.
• Review the full proxy statement for detailed biographies of the newly elected directors and the rationale for the auditor ratification.
• Check subsequent filings for the Company's financial results for the fiscal year ending December 31, 2010, as this 8-K contains no financial data.